CN114269782A - 抗tigit抗体及其应用 - Google Patents

抗tigit抗体及其应用 Download PDF

Info

Publication number
CN114269782A
CN114269782A CN202080051389.6A CN202080051389A CN114269782A CN 114269782 A CN114269782 A CN 114269782A CN 202080051389 A CN202080051389 A CN 202080051389A CN 114269782 A CN114269782 A CN 114269782A
Authority
CN
China
Prior art keywords
antibody
amino acid
acid sequence
seq
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080051389.6A
Other languages
English (en)
Other versions
CN114269782B (zh
Inventor
孟琴
姚剑
冯辉
姚盛
武海
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Junshi Biosciences Co Ltd
Suzhou Junmeng Biosciences Co Ltd
Original Assignee
Shanghai Junshi Biosciences Co Ltd
Suzhou Junmeng Biosciences Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Junshi Biosciences Co Ltd, Suzhou Junmeng Biosciences Co Ltd filed Critical Shanghai Junshi Biosciences Co Ltd
Publication of CN114269782A publication Critical patent/CN114269782A/zh
Application granted granted Critical
Publication of CN114269782B publication Critical patent/CN114269782B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

提供了与TIGIT特异性结合的抗体或其抗原结合片段及其组合物。还提供了编码所述抗体或其抗原结合片段的核酸分子，用于表达所述抗体或其抗原结合片段的表达载体和宿主细胞，以及其治疗和诊断用途。

Description

PCT国内申请，说明书已公开。

Claims (20)

  1. PCT国内申请，权利要求书已公开。
CN202080051389.6A 2019-07-15 2020-07-14 抗tigit抗体及其应用 Active CN114269782B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019106343099 2019-07-15
CN201910634309 2019-07-15
PCT/CN2020/101883 WO2021008523A1 (zh) 2019-07-15 2020-07-14 抗tigit抗体及其应用

Publications (2)

Publication Number Publication Date
CN114269782A true CN114269782A (zh) 2022-04-01
CN114269782B CN114269782B (zh) 2023-12-29

Family

ID=74210102

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080051389.6A Active CN114269782B (zh) 2019-07-15 2020-07-14 抗tigit抗体及其应用

Country Status (13)

Country Link
US (1) US20220363754A1 (zh)
EP (1) EP4001308A4 (zh)
JP (1) JP2022541022A (zh)
KR (1) KR20220042258A (zh)
CN (1) CN114269782B (zh)
AU (1) AU2020314129A1 (zh)
BR (1) BR112022000628A2 (zh)
CA (1) CA3146986A1 (zh)
CL (1) CL2022000096A1 (zh)
IL (1) IL289656A (zh)
MX (1) MX2022000586A (zh)
WO (1) WO2021008523A1 (zh)
ZA (1) ZA202201464B (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021247591A1 (en) 2020-06-02 2021-12-09 Arcus Biosciences, Inc. Antibodies to tigit
WO2022152245A1 (zh) * 2021-01-14 2022-07-21 上海君实生物医药科技股份有限公司 抗tigit抗体药物组合物及其用途
WO2023138639A1 (zh) * 2022-01-24 2023-07-27 原启生物科技(上海)有限责任公司 靶向tigit的抗原结合蛋白及其用途
WO2023215719A1 (en) 2022-05-02 2023-11-09 Arcus Biosciences, Inc. Anti-tigit antibodies and uses of the same

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107148430A (zh) * 2014-08-19 2017-09-08 默沙东公司 抗tigit抗体
CN107207594A (zh) * 2014-12-23 2017-09-26 百时美施贵宝公司 针对tigit的抗体
WO2018102746A1 (en) * 2016-12-02 2018-06-07 Rigel Pharmaceuticals, Inc. Antigen binding molecules to tigit
CN108137691A (zh) * 2015-09-02 2018-06-08 耶路撒冷希伯来大学伊萨姆研究发展有限公司 特异性针对人类t-细胞免疫球蛋白和itim结构域（tigit）的抗体
CN108290936A (zh) * 2015-08-14 2018-07-17 默沙东公司 抗tigit抗体
CN108368176A (zh) * 2015-10-01 2018-08-03 波滕扎治疗公司 抗tigit抗原结合蛋白及其使用方法
WO2018204363A1 (en) * 2017-05-01 2018-11-08 Agenus Inc. Anti-tigit antibodies and methods of use thereof
CN109071656A (zh) * 2017-01-05 2018-12-21 源晟生物制药股份有限公司 检查点调节物拮抗剂
CN109384846A (zh) * 2018-09-25 2019-02-26 合肥瑞达免疫药物研究所有限公司 能够结合tigit的抗体或其抗原结合片段及用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP2277532A1 (en) 2002-09-11 2011-01-26 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
DK2578685T3 (da) 2005-08-23 2019-06-03 Univ Pennsylvania Rna indeholende modificerede nukleosider og fremgangsmåder til anvendelse deraf
MX364200B (es) 2008-04-09 2019-04-16 Genentech Inc Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad.
CN104250302B (zh) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
PL3021869T3 (pl) 2013-07-16 2020-11-16 F. Hoffmann-La Roche Ag Sposoby leczenia nowotworu z użyciem antagonistów wiązania osi PD-1 i inhibitorów TIGIT
KR20200087283A (ko) * 2015-09-25 2020-07-20 제넨테크, 인크. 항-tigit 항체 및 이의 이용 방법
MX2018010485A (es) * 2016-03-04 2019-01-10 Jn Biosciences Llc Anticuerpos para inmunoreceptor de celulas t con dominios de ig e itim (tigit).
DK3347379T5 (da) * 2016-08-17 2020-06-15 Compugen Ltd Anti-tigit-antistoffer, anti-pvrig-antistoffer og kombinationer deraf
CN108456251A (zh) 2017-02-21 2018-08-28 上海君实生物医药科技股份有限公司 抗pd-l1抗体及其应用

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107148430A (zh) * 2014-08-19 2017-09-08 默沙东公司 抗tigit抗体
CN107207594A (zh) * 2014-12-23 2017-09-26 百时美施贵宝公司 针对tigit的抗体
CN108290936A (zh) * 2015-08-14 2018-07-17 默沙东公司 抗tigit抗体
CN108137691A (zh) * 2015-09-02 2018-06-08 耶路撒冷希伯来大学伊萨姆研究发展有限公司 特异性针对人类t-细胞免疫球蛋白和itim结构域（tigit）的抗体
CN108368176A (zh) * 2015-10-01 2018-08-03 波滕扎治疗公司 抗tigit抗原结合蛋白及其使用方法
WO2018102746A1 (en) * 2016-12-02 2018-06-07 Rigel Pharmaceuticals, Inc. Antigen binding molecules to tigit
CN109071656A (zh) * 2017-01-05 2018-12-21 源晟生物制药股份有限公司 检查点调节物拮抗剂
WO2018204363A1 (en) * 2017-05-01 2018-11-08 Agenus Inc. Anti-tigit antibodies and methods of use thereof
CN109384846A (zh) * 2018-09-25 2019-02-26 合肥瑞达免疫药物研究所有限公司 能够结合tigit的抗体或其抗原结合片段及用途

Also Published As

Publication number Publication date
JP2022541022A (ja) 2022-09-21
EP4001308A1 (en) 2022-05-25
EP4001308A4 (en) 2023-08-23
KR20220042258A (ko) 2022-04-04
CL2022000096A1 (es) 2022-11-11
BR112022000628A2 (pt) 2022-03-03
IL289656A (en) 2022-03-01
CA3146986A1 (en) 2021-01-21
US20220363754A1 (en) 2022-11-17
MX2022000586A (es) 2022-03-04
AU2020314129A1 (en) 2022-02-24
CN114269782B (zh) 2023-12-29
ZA202201464B (en) 2023-08-30
WO2021008523A1 (zh) 2021-01-21

Similar Documents

Publication Publication Date Title
JP5828909B2 (ja) 腫瘍関連抗原結合抗体を含む併用療法
KR20180004277A (ko) Pdl-1 항체, 그 약학적 조성물 및 그 용도
CN114269782B (zh) 抗tigit抗体及其应用
JP2021527714A (ja) 抗ｐｄ−１抗体及びその使用
EP3087097B1 (en) Multifunctional antibodies binding to egfr and met
JP7455388B2 (ja) 抗ｄｌｌ３抗体及びその使用
US20230295301A1 (en) Anti-ctla-4 antibody and use thereof
US20220372161A1 (en) Antibodies against the poliovirus receptor (pvr) and uses thereof
CN114341186A (zh) 双特异性抗LRRC15和CD3ε抗体
EP4292611A1 (en) Anti-cd112r antibody and use thereof
WO2022228431A1 (zh) 抗pd-l1单域抗体及其用途
EP4180457A1 (en) Anti-cldn-18.2 antibody and use thereof
WO2023098785A1 (zh) 抗4-1bb抗体及其用途
JP2024509916A (ja) インテグリンヘテロ二量体に対する抗体およびその使用
CN117510641A (zh) 靶向cd112r和tigit的双特异性抗体及其用途
EA045980B1 (ru) Антитела против рецептора полиовируса (pvr) и их применение
CA3206413A1 (en) Antibodies against cd112r and uses thereof
CN116323658A (zh) 靶向PD-1或PD-L1和TGF-β的双功能蛋白及其医药用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant